Background Oesophageal cancer prognosis remains poor owing to the inability to detect the disease at an early stage. Nontissue (serum, urinary or salivary) biomarkers potentially offer less invasive methods to aid early detection of oesophageal cancer. We aimed to systematically review studies assessing the relationship between nontissue biomarkers and subsequent development of oesophageal cancer. Methods Using terms for biomarkers and oesophageal cancer, Medline, EMBASE and Web of Science were systematically searched for longitudinal studies, published until April 2016, which assessed the association between nontissue biomarkers and subsequent oesophageal cancer risk. Random effects meta-analyses were used to calculate pooled relative risk (RR) and 95% confidence intervals (CIs), where possible. Results A total of 39 studies were included. Lower serum pepsinogen I concentrations were associated with an increased risk of oesophageal squamous cell carcinoma (n = 3 studies, pooled RR = 2.20, 95% CI: 1.31-3.70). However, the association for the pepsinogen I : II ratio was not statistically significant (n = 3 studies, pooled RR = 2.22, 95% CI: 0.77-6.40), with a large degree of heterogeneity observed (I 2 = 68.0%). Higher serum glucose concentrations were associated with a modestly increased risk of total oesophageal cancer (n = 3 studies, pooled RR = 1.27, 95% CI: 1.02-1.57). No association was observed for total cholesterol and total oesophageal cancer risk (n = 3 studies, pooled RR = 0.95, 95% CI: 0.58-1.54). Very few studies have assessed other biomarkers for meta-analyses. Conclusion Serum pepsinogen I concentrations could aid early detection of oesophageal squamous cell carcinoma. More prospective studies are needed to determine the use of other nontissue biomarkers in the early detection of oesophageal cancer.
Introduction
Oesophageal cancer has a very poor prognosis, with less than 20% of patients surviving for more than 5 years from diagnosis [1, 2] . Poor survival is attributable to late clinical presentation with advanced disease, with less than a quarter of cases diagnosed at stage I or II [3, 4] .
The two main histological subtypes, oesophageal adenocarcinoma (OAC) and oesophageal squamous cell carcinoma (OSCC), differ by aetiology and geographical incidence, with OAC more common in Western populations (>60% of oesophageal cancers) and OSCC more common (>90%) in Eastern populations, but they share a poor prognosis [2, 5, 6] .
Despite the high sensitivity of endoscopy as a diagnostic tool, a national screening program for oesophageal cancer has not been justified owing to the high cost, the invasiveness of the procedure and the psychological burden [7, 8] . Cytosponge screening for Barrett's oesophagus (BO) and oesophageal cancer is currently being trialled in patients with heartburn symptoms [9, 10] , but otherwise the potential for viable screening options seems limited. Although endoscopy can also identify patients with BO, the precursor lesion of OAC or squamous dysplasia, the precursor lesion of OSCC, risk-stratification tools for identifying individuals at highest risk of neoplastic progression are limited. Surveillance program among patients with BO place a considerable strain on gastroenterology resources and patients owing to the limited risk stratification [7] .
Identification of cheaper, less invasive methods to identify individuals at risk of developing oesophageal cancer are needed to improve screening and surveillance options within the general public and patients with precancerous lesions, respectively [7] . Although tissue biomarkers offer promise in the early detection of oesophageal cancer, blood, urine or salivary tests could offer a simpler and less invasive alternative.
A large number of epidemiological studies have assessed the role of nontissue biomarkers in oesophageal cancer risk [11, 12] . However, many of the studies have been cross-sectional/retrospective, whereby the biomarker was used as an aid to oesophageal cancer diagnosis.
Prospective studies are needed to determine if the changes in biomarkers occur early enough in cancer development to identify high-risk individuals and aid early diagnosis.
An examination of biomarkers associated with oesophageal cancer may also provide insight into the mechanisms and aetiology of oesophageal cancer development.
The aim of this systematic review is to summarize evidence from all prospective studies that have assessed the relationship between blood, urinary and salivary biomarkers and risk of oesophageal cancer, to identify potential aides for risk stratification and early diagnosis of oesophageal cancer.
Methods

Literature search
To investigate blood, urine and salivary based biomarkers in the early diagnosis of oesophageal cancer, three databases, Medline (1947-), EMBASE (1974-) and Web of Science (1980-), were systematically searched from inception to 29 April 2016 for primary studies in humans, published in any language. Databases were searched using exploded subject headings and combinations of keywords for biomarkers and oesophageal cancer (see Supplementary Table 1 , Supplemental digital content 1, http://links.lww.com/EJGH/ A240 for full search terms). Reference lists and manual searches were used to identify any additional published studies.
Eligibility criteria
Titles and abstracts of articles identified through the electronic search were reviewed independently, in duplicate, by two reviewers (from A.K., H.C., U.M., R.G. and A.S.). The full text of articles for possible inclusion was then independently reviewed by two investigators (from A.K., H.C., U.M., R.G. and A.S.). If there was disagreement between the reviewers at either stage, an independent review was undertaken by a third reviewer and a consensus reached.
Criteria for inclusion in the review included the following: assessment of a nontissue (blood, urinary or salivary) based biomarker (including circulating epigenetic markers) in relation to total oesophageal cancer (any histological type), OAC or OSCC risk. Studies reporting only on esophagogastric junction cancers or high-grade dysplasia of the oesophagus, or not separating these from oesophageal tumours were not included. Included studies had to have at least a 6-month follow-up period after biomarker assessment (to exclude prevalent cancers with diagnostic delays). Cross-sectional studies where the biomarkers were measured at, or close to, the time of diagnostic assessment or following diagnosis were excluded. To ensure a narrow scope and to minimize repetition of existing systematic reviews, oesophageal tissue biomarkers, blood-based genetic polymorphisms and infectious agents were not eligible for inclusion [13, 14] . Studies using diagnoses of medical conditions in medical records as a proxy for biomarker status were not included owing to potential differences in the exact biomarker measurement used for diagnosis [e.g. either high total cholesterol or high low-density lipoprotein (LDL) cholesterol could be used to diagnose hypercholesterolaemia]. Studies of biomarkers and oesophageal cancer mortality were not included. Participants included in individual studies could be healthy at biomarker assessment or have oesophageal conditions other than oesophageal cancer, such as BO.
Data extraction
Data extraction was performed by an experienced author (A.K.). Extracted information from each of the individual studies included the following: author names and date of publication, study setting, study population, participant demographics and baseline characteristics, biomarkers assessed as well as the timing and method of assessment, the sample type, study methodology, recruitment and study completion rates and outcomes of interest. Articles in non-English languages were translated where necessary. The Newcastle-Ottawa scale for cohort studies was used to assess study quality [15] .
Statistical analysis
Stata 14 software (Stata Corporation, College Station, Texas, USA) was used for data analysis. Random effects meta-analyses were used to examine the pooled association between each biomarker and each type of oesophageal cancer (total, OAC, or OSCC) if at least three eligible studies had assessed the association. Adjusted results were used where possible. A χ 2 -test for heterogeneity was calculated and the I 2 statistic determined, to estimate the proportion of variation between study results attributable to heterogeneity rather than chance [16] . Heterogeneity was considered high if I 2 statistic was above 75% [16] . If studies only provided results stratified by participant characteristics (such as sex), the results were combined using preliminary meta-analysis before entry into the overall meta-analysis. Owing to low study numbers identified for each biomarker, publication bias could not be formally assessed [17] . Where studies included in metaanalyses used multiple classifications, or cut-offs for biomarkers concentrations (e.g. quartiles, categorical and continuous), we chose results based on similarity of classification to other studies (most studies used tertiles/ quartiles).
Results
The searches identified 15 334 study records (Medline = 3210, EMBASE = 6414 and Web of Science = 5710). After removal of duplicates, 6995 studies remained. After a review of titles and abstracts, 82 articles were chosen for full-text review, from which 36 studies were eligible for inclusion. An additional three studies eligible for inclusion were identified by manual searches and review of reference lists [18] [19] [20] , meaning a total of 39 studies were included in the review ( Fig. 1 and Table 1 ) and are further described by broad classification of biomarker type.
Fifteen studies were conducted in Eastern or South-East Asia populations, 12 studies were conducted in European populations and eight studies were conducted in North American populations. Seven studies were conducted among males only. The studies were mostly conducted within cohorts with a mean BMI below 25, though some studies were conducted among cohorts with BO at baseline and had average BMI above 25 (Table 1) . Most studies were judged to be of a good (n = 31 studies) or fair quality (n = 6 studies), though two studies assessing exposure to toxic chemical within worker cohorts were judged to be poor quality (Table 2) .
Lipid-and glucose-related biomarkers
We identified seven studies that assessed the association between serum lipid or glucose biomarkers and risk of oesophageal cancer (Supplementary Table 2 , Supplemental digital content 1, http://links.lww.com/EJGH/A240).
A meta-analysis of five studies [18, 19, [21] [22] [23] found no association between total serum cholesterol concentrations and risk of total oesophageal cancer [pooled relative risk (RR) = 1.00, 95% confidence interval (CI): 0.79-1.27, I 2 = 36.8%, Fig. 2 ]. In addition, Lindkvist et al. [54] provided a breakdown by type of oesophageal cancer and found no association between high total cholesterol and risk of either OAC or OSCC (Supplementary Table 2 , Supplemental digital content 1, http://links.lww.com/ EJGH/A240).
Wulaningsih et al. [23] also tested subtypes of cholesterol-related measures, though could not adjust for BMI. Strong inverse associations with risk of oesophageal cancer were found for LDL cholesterol, the LDL : highdensity lipoprotein (HDL) ratio and the Apo B : ApoA ratio in that study. No associations were seen for HDL cholesterol, total : HDL cholesterol ratio, the triglyceride : HDL ratio, ApoB or ApoA concentrations. A positive association was observed for triglyceride concentrations as individuals in the highest quartile of triglyceride concentrations had more than double the risk of oesophageal cancer. However, Lindkvist et al. [54] found a weaker association for triglycerides, which was not statistically significant for either OAC or OSCC. Ahn et al. [21] found a nonsignificant positive association between HDL cholesterol concentrations and risk of oesophageal cancer.
Wulaningsih et al. [23] , Stocks et al. [20] and Jee et al. [52] all assessed the association between glucose concentrations and oesophageal cancer risk. A meta-analysis of these three studies found a 27% increase in risk of total oesophageal cancer in individuals with higher glucose concentrations (pooled RR = 1.27, 95% CI: 1.02-1.57) with no evidence of heterogeneity (I 2 = 0.0%) (Fig. 3) .
Only Lindkvist et al. [54] provided a breakdown by cancer type with the results indicative that glucose concentrations were more strongly associated with OSCC risk than OAC risk.
Duggan et al. [55] assessed the association between Homeostatic Model Assessment (HOMA) scores, calculated by multiplying insulin and glucose concentrations, and risk of OAC among a cohort of individuals with BO and found evidence of an association when assessed continuously (RR = 1.64, 95% CI: 1.08-2.48).
Nutrition-related biomarkers
We identified 16 studies that assessed the association between nutrition-related biomarkers and oesophageal cancer (Supplementary Table 3 , Supplemental digital content 1, http://links.lww.com/EJGH/A240).
Eight studies assessed the role of nutrition-related biomarkers and total oesophageal cancer risk. Kimm et al. [35] found that individuals with higher aspartate transaminase : alanine transaminase ratios (a biomarker associated with liver damage often caused by alcohol consumption) had a higher risk of oesophageal cancer. Tsuboya et al. [46] found no association between γ-glutamyltransferase concentrations (associated with excessive alcohol intake and liver disease) Oesophageal cancer biomarkers review Kunzmann et al.
www.eurojgh.com and risk of total oesophageal cancer. Knekt et al. [56] did not find an association for β-carotene, and the others have not been investigated previously. No associations were observed for α-tocopherol [56] , selenium [56] , retinol [56] , tea polyphenols [36] , calcium [33] and phosphate [34] and risk of total oesophageal cancer. Eight studies assessed the role of nutrition-related biomarkers in OSCC risk, and three studies assessed the role of nutrition-related biomarkers in OAC risk. Murphy et al. [43] found a significant reduction in OSCC risk among individuals with higher serum cysteine concentrations. Fanidi et al. [42] found a significant increase in OSCC risk among individuals with higher serum folate concentrations but not other B-vitamins, or one-carbon products (homocysteine/methionine). Some of the results from studies assessing OSCC risk contrast with the results from separate studies of total oesophageal cancer described earlier, with significant inverse associations seen for selenium [41] and α-tocopherol [38] , but null results for β-carotene and β-cryptoxanthin [39] . Null associations were also seen in individual studies for vitamin C, retinol and lutein [39, 40, 56] . Chen et al. [53] found evidence of an association between serum 25-hydroxyvitamin D and OSCC; however, Abnet et al. [32] did not find an association with OSCC or OAC in an analysis of data from eight prospective cohorts. Takata et al. [37] also found no association between serum selenium concentrations and risk of progression to OAC among a cohort of individuals with BO.
Metabolic/digestive-related biomarkers
We identified nine studies that assessed the association between biomarkers related to metabolism or inflammation and oesophageal cancer risk (Supplementary Table 4 , Supplemental digital content 1, http://links.lww.com/ EJGH/A240).
A random effects meta-analyses of three studies [27] [28] [29] found that lower pepsinogen I (PGI) concentrations were associated with increased risk of OSCC (pooled (Fig. 4) . The same studies [27] [28] [29] also assessed the association between the PGI : PGII ratio and risk of OSCC but did not find evidence of an association (pooled RR = 1.44, 95% CI: 0.42-4.91), with a large degree of heterogeneity (I 2 = 75.7%) (Fig. 5) . Sensitivity analyses indicated that heterogeneity was lowered after the exclusion of results from Cook et al. [27] (pooled RR = 0.91, 95% CI: 0.37-2.20, I 2 = 18.3%).
Duggan et al. [55] found a significant positive linear association between serum leptin concentrations, but not adiponectin, and risk of OAC in individuals with BO, including when limiting to cancers diagnosed within 3 years of baseline blood sampling (hazard ratio = 2.51, 95% CI: 1.09-5.81). However, the association was only statistically significant in continuous analysis and has yet to be tested in other studies. No studies identified assessed leptin and adiponectin and OSCC risk. Columns indicate the number of cases and noncases with low (reference category) and high total serum glucose concentrations, relative risk (ES) [95% confidence intervals (CIs)] and weighting. De Martel et al. [24] found a borderline association between high serum ghrelin concentrations and lower OAC risk in patients with BO. Similarly, Murphy et al. [30] found lower ghrelin levels were associated with an increased risk of OSCC.
Inflammation-related biomarkers
Keeley et al. [31] found evidence of strong positive associations between various inflammation-related biomarkers, including tumour necrosis factor (TNF)-α, TNF-β, monocyte chemotactic protein 3, interleukin (IL)-1R, IL-13 and granulocyte/macrophage colony-stimulating factor and the risk of OSCC.
Two studies assessed the association between inflammationrelated biomarkers in BO cohorts. Hardikar et al. [25] found no evidence of an association between C-reactive protein, IL-6, isoprostane, TNF-α or TNF-β and risk of progression to OAC. Siahpush et al. [26] found no evidence of an association between insulin-like growth factor (IGF) 1 and risk of OAC.
Miscellaneous biomarkers
Results of individual studies examining the association between miscellaneous biomarkers and risk of oesophageal cancer are listed in Supplementary Table 5 (Supplemental digital content 1, http://links.lww.com/ EJGH/A240). Haemoglobin was not associated with risk Oesophageal cancer biomarkers review Kunzmann et al.
www.eurojgh.comof oesophageal cancer, even when limiting the time from measurement to diagnosis to 3 years, although there was evidence of a trend which suggested a stronger association when limiting to oesophageal cancer diagnoses within a year of biomarker measurement [45] . Leucocyte telomere length was found to have a strong association with risk of progression to OAC among a cohort of individuals with BO in one study [49] , but it requires confirmation in other studies. However, lymphocyte mutagen sensitivity, a marker for the ability to repair DNA damage, was not found to be associated with risk of progression among the same BO cohort [50] .
Biomarkers of smoking behaviours such as total N ′-nitrosonornicotine, a tobacco-specific carcinogen, were found to be associated with risk of oesophageal cancer among male smokers in one study [44] .
No association was found between sphingosines and risk of OSCC [51] .
Exposure to toxins was also investigated, though neither urine levels of lead or trichloroethylene among workers in jobs at risk of exposure to these chemicals was found to be associated with oesophageal cancer risk [47, 48] .
Discussion
This systematic review sought to examine nontissue biomarkers associated with oesophageal cancer risk, to identify biomarkers that could be used to predict oesophageal cancer development. The review identified 39 studies that assessed the role of various biomarkers in oesophageal cancer risk. Meta-analyses revealed an association between serum PGI concentrations and OSCC risk (n = 3 studies) and between serum glucose concentrations and total oesophageal cancer risk (n = 3 studies). No associations were observed for total cholesterol and total oesophageal cancer risk (n = 5 studies). However, for most biomarkers, too few studies had been conducted to combine results using meta-analyses and some biomarkers with promising cross-sectional findings remain to be tested using prospective analyses.
The association between PGI concentrations was consistent across the three studies [27] [28] [29] included in the meta-analysis and indicated that individuals with lower PGI concentrations had more than double the subsequent risk of OSCC. The association was similar between two studies in China and one in Finland (limited to males) suggesting geographical variation was not indicated. Similar effect sizes were observed in a meta-analysis of the same three studies assessing the association between the PGI : PGII ratio and OSCC risk, though the result was not statistically significant and heterogeneity was high. The results are supported by a study indicating an association between PG concentrations and risk of oesophageal squamous dysplasia [57] . Lower PGI concentrations and a lower PGI : PGII ratio are thought to be indicators of gastric atrophy [58, 59] . Lower PGI concentrations could be related to OSCC through bacterial overgrowth resulting from the reduced gastric acid production during gastric atrophy [60] [61] [62] or duodenal reflux [27, 63] . Gastric atrophy is often caused by Helicobacter pylori infections, and H. pylori infection has previously been linked to OSCC risk in Eastern populations [64] . However, the association between PGI and OSCC risk appears to be independent of H. pylori status as the studies included in the current review either adjusted for H. pylori or did not find similar evidence of an association between H. pylori and OSCC risk in separate analyses. Although serologic amnesia is possible, the results suggest that PG measurement could potentially aid OSCC risk stratification independently of H. pylori measurement by identifying individuals at higher OSCC risk. PGI and the PGI : PGII ratio have previously been considered as part of gastric cancer screening programs in some countries [58, 59, 65] . However, questions remained about the cost-effectiveness. Should later studies confirm the results of the current metaanalysis, policy makers could assess the potential additional benefit of early OSCC detection when assessing whether to implement cancer screening programs measuring PG concentrations/ratios, particularly in high-risk areas for OSCC [65] .
The lack of an association between total cholesterol concentrations and risk of total oesophageal cancer in a meta-analysis of five studies could be because of the different actions of each type of cholesterol. Wulaningsih et al. [23] found stronger inverse association between more specific cholesterol markers, including LDL cholesterol, the ratio of LDL : HDL cholesterol and the ApoB : ApoA ratio and the risk of oesophageal cancer but were unable to adjust for BMI which could confound the associations. Therefore, although an association between total cholesterol concentrations and oesophageal cancer risk appears unlikely, further detailed investigations into the association between more specific lipid biomarkers and oesophageal cancer risk independently of BMI seem warranted.
The association between serum glucose and total oesophageal cancer risk was modest (27%), but notably consistent across the three studies in the meta-analysis, despite geographical differences (two studies from Europe and one study from South Korea). Two of the three studies included adjustment for BMI [54] or reported no change after adjustment for BMI [52] , suggesting the results may be independent of BMI and could add predictive value to potential oesophageal cancer risk-stratification models. The findings are consistent with the results of a systematic review that found a 27% increased risk of oesophageal cancer in individuals with diabetes mellitus in a pooled analysis of cohort studies [66] . However, the similarity could arise, as the studies included in the current review used measurements recorded in clinical databases, so individuals may have been deemed to be at high risk of diabetes, meaning the results may not be representative of low-risk individuals. The result is also consistent with an observation by Duggan et al. [55] of an association between HOMA scores, calculated by multiplying serum insulin and glucose concentrations, and the risk of OAC. The potential mechanism mediating the association between serum glucose concentrations and oesophageal cancer could be oxidative stress related to hyperglycaemia or growth promotion by IGF [67] . However, for the latter, it is important to note that no association was observed between IGF and OAC risk in a study by Siahpush et al. [26] included in the current review, despite promising findings from nonprospective studies [68] . Only one study in the current review provided a breakdown by histological subtype of oesophageal cancer, therefore more studies will be needed to assess whether the associations with serum glucose are similar for both OAC and OSCC. Nevertheless, the review suggests that serum glucose concentrations could potentially aid risk stratification of individuals for oesophageal cancer risk, especially given the simplicity of blood glucose testing. However, a check of diabetes history may suffice, and the modest strength of the association with oesophageal cancer risk means that the potential clinical benefit in terms of identifying highrisk individuals is likely to be limited unless incorporated into a wider panel of biomarkers or risk-stratification measures.
Despite the large number of biomarkers assessed, most biomarkers have been tested by very few studies for strong conclusions to be formed, perhaps owing to the difficulty in assessing rarer cancers such as oesophageal cancer in prospective studies. None of the studies identified assessed salivary biomarkers, and very few assessed urinary biomarkers, despite promising findings for other gastrointestinal cancers [69] . For other novel blood markers, such as serum anti-p53 and microRNAs, recent evidence from cross-sectional studies suggests that serum concentrations differ between patients with oesophageal cancer and cancer-free controls [11, 12, 70] , but no prospective studies have been conducted so these biomarkers were not included in this review. Further studies are needed to assess nontissue biomarkers given the public and clinical demand for blood-based biomarkers [71, 72] .
The review provides a comprehensive assessment of the existing evidence of nontissue biomarkers in oesophageal cancer risk and has identified promising associations between PGI concentrations and OSCC risk. A limitation was that many studies examined total oesophageal cancer risk without providing separate results for OAC and OSCC, despite the substantial differences between OAC and OSCC [73] in terms of biology, risk factors and patterns of incidence, possibly to maximize statistical power. Many of the included studies aimed to identify aetiological rather than early diagnostic biomarkers, which precluded an examination of the association with oesophageal cancers occurring within a period close to biomarker measurement (< 3 years) useful for early detection [45] . Similarly, the biomarkers assessed were only measured at one point in time, which could also limit the ability to identify the optimal timepoint of biomarker measurement.
Conclusion
Some nontissue biomarkers, such as serum PGI concentrations, may offer promise in identifying individuals at risk of oesophageal cancer which could help target screening or surveillance programs and aid in the early detection of oesophageal cancer. However, very few studies have assessed the same biomarkers, and some promising biomarkers remain to be tested prospectively to adequately develop a biomarker panel for risk stratification or for use in future oesophageal cancer screening programs.
